Systems biology approach for in vivo photodynamic therapy optimization of ruthenium-porphyrin compounds

Journal of Photochemistry and Photobiology B: Biology

Volumn 117, Issue , 2012, Pages 80-89

  Pernot, Marlène ^a,b   Bastogne, Thierry ^a,b,c,g   Barry, Nicolas P E ^d   Therrien, Bruno ^d   Koellensperger, Gunda ^e   Hann, Stephan ^e   Reshetov, Vadzim ^a,b,f   Barberi Heyob, Muriel ^a,b,g  

^a UNIVERSITÉ DE LORRAINE   (France)

^b CNRS   (France)

^c INRIA   (France)

^d UNIVERSITY OF NEUCHÂTEL   (Switzerland)

^e UNIVERSITY OF NATURAL RESOURCES AND LIFE SCIENCES   (Austria)

^f BELARUSIAN STATE UNIVERSITY   (Belarus)

^g GDR CNRS 3049   (France)

Author keywords

Combined phototherapy; Experimental design approach; Human oral carcinoma bearing nude mice; Porphyrin; Ruthenium

Indexed keywords

GLASS FIBER; PHOTOSENSITIZING AGENT; PORPHYRIN DERIVATIVE; RUTHENIUM COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONJUGATE; CONTROLLED STUDY; EXPERIMENTAL DESIGN; FEMALE; FLUORESCENCE MICROSCOPY; FLUOROMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; MASS SPECTROMETRY; MOUSE; MOUTH CARCINOMA; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROCESS OPTIMIZATION; SYSTEMS BIOLOGY; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; DRUG DISCOVERY; FEMALE; HUMANS; INTRACELLULAR SPACE; METALLOPORPHYRINS; MICE; MICE, NUDE; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; RUTHENIUM; SPECTRUM ANALYSIS; SYSTEMS BIOLOGY;

MUS; MUS MUSCULUS; TETRA;

EID: 84867460321     PISSN: 10111344     EISSN: 18732682     Source Type: Journal    
DOI: 10.1016/j.jphotobiol.2012.08.012     Document Type: Article

References (42)

1. H. Benachour, C. Frochot, R. Vanderesse, F. Guillemin, M. Barberi-Heyob, in: E. Salvatti (Eds.), Targeting Strategies in Photodynamic Therapy, Nova Publishers, 2011, pp. 1-38.
2. C. Lottner, R. Knuechel, G. Bernhardt, and H. Brunner Distribution and subcellular localization of a water-soluble hematoporphyrin-platinum(II) complex in human bladder cancer cells Cancer Lett. 215 2 2004 167 177
3. C. Lottner, R. Knuechel, G. Bernhardt, and H. Brunner Combined chemotherapeutic and photodynamic treatment on human bladder cells by hematoporphyrin-platinum(II) conjugates Cancer Lett. 203 2 2004 171 180
4. J. Mao, Y. Zhang, J. Zhu, C. Zhang, and Z. Guo Molecular combo of photodynamic therapeutic agent silicon(iv) phthalocyanine and anticancer drug cisplatin Chem. Commun. (Camb) 8 2009 908 910
5. C. Lottner, K.C. Bart, G. Bernhardt, and H. Brunner Hematoporphyrin- derived soluble porphyrin-platinum conjugates with combined cytotoxic and phototoxic antitumor activity J. Med. Chem. 45 10 2002 2064 2078
6. Y.S. Kim, R. Song, D. Hyun Kim, M.J. Jun, and Y.S. Sohn Synthesis, biodistribution and antitumor activity of hematoporphyrin-platinum(II) conjugates Bioorg. Med. Chem. 11 8 2003 1753 1760
7. Y.P. Ho, S.C. Au-Yeung, and K.K. To Platinum-based anticancer agents: innovative design strategies and biological perspectives Med. Res. Rev. 23 5 2003 633 655
8. E. Cvitkovic Ongoing and unsaid on oxaliplatin: the hope Brit. J. Cancer 77 4 1998 8 11
9. M.J. Hannon Supramolecular DNA recognition Chem. Soc. Rev. 36 2 2007 280 295
10. G. Jaouen Bioorganometallics: Biomolecules, Labeling, Medicine G. Jouen, 2006 John Wiley & Sons
11. F. Schmitt, P. Govindaswamy, G. Suss-Fink, W.H. Ang, P.J. Dyson, L. Juillerat-Jeanneret, and B. Therrien Ruthenium porphyrin compounds for photodynamic therapy of cancer J. Med. Chem. 51 6 2008 1811 1816
12. F. Schmitt, P. Govindaswamy, O. Zava, G. Suss-Fink, L. Juillerat-Jeanneret, and B. Therrien Combined arene ruthenium porphyrins as chemotherapeutics and photosensitizers for cancer therapy J. Biol. Inorg. Chem. 14 1 2009 101 109
13. T. Gianferrara, I. Bratsos, E. Iengo, B. Milani, A. Ostric, C. Spagnul, E. Zangrando, and E. Alessio Synthetic strategies towards ruthenium-porphyrin conjugates for anticancer activity Dalton Trans. 48 2009 10742 10756
14. T. Gianferrara, B. Serli, E. Zangrando, E. Iengo, and E. Alessio Pyridylporphyrins peripherally coordinated to ruthenium-nitrosyls, including the water-soluble Na4[Zn.4′TPyP{RuCl4(NO)}4]: synthesis and structural characterization New J. Chem. 29 2005 895 903
15. W.H. Ang, and P.J. Dyson Classical and non-classical ruthenium-based anticancer drugs: towards targeted chemotherapy Eur. J. Chem. 2006 4003 4018
16. F. Kratz, M. Hartmann, B. Keppler, and L. Messori The binding properties of two antitumor ruthenium(III) complexes to apotransferrin J. Biol. Chem. 269 4 1994 2581 2588
17. M. Klajner, P. Hebraud, C. Sirlin, C. Gaiddon, and S. Harlepp DNA binding to an anticancer organo-ruthenium complex J. Phys. Chem. B 114 44 2010 14041 14047
18. A. Levina, A. Mitra, and P.A. Lay Recent developments in ruthenium anticancer drugs Metallomics 1 6 2009 458 470
19. F. Schmitt, M. Auzias, P. Stepnicka, Y. Sei, K. Yamaguchi, G. Süss-Fink, B. Therrien, and L. Juillerat-Jeanneret Sawhorse-type diruthenium tetracarbonyl complexes containing porphyrin-derived ligands as highly selective photosensitizers for female reproductive cancer cells J. Biol. Inorg. Chem. 14 2009 693 701
20. M.A. Biel Photodynamic therapy of head and neck cancers Methods Mol. Biol. 635 2010 281 293
21. J. Gravier, R. Schneider, C. Frochot, T. Bastogne, F. Schmitt, J. Didelon, F. Guillemin, and M. Barberi-Heyob Improvement of meta- tetra(hydroxyphenyl)chlorin-like photosensitizer selectivity with folate-based targeted delivery. Synthesis and in vivo delivery studies J. Med. Chem. 51 13 2008 3867 3877
22. L. Tirand, T. Bastogne, D. Bechet, M. Linder, N. Thomas, C. Frochot, F. Guillemin, and M. Barberi-Heyob Response surface methodology: an extensive potential to optimize in vivo photodynamic therapy conditions Int. J. Radiat. Oncol. Biol. Phys. 75 1 2009 244 252
23. T. Bastogne, A. Samson, P. Vallois, S. Wantz-Mézières, S. Pinel, D. Bechet, and M. Barberi-Heyob Phenomenological modeling of tumor diameter growth based on a mixed effects model J. Theor. Biol. 262 2010 544 552
24. P.J. Houghton, C.L. Morton, C. Tucker, D. Payne, E. Favours, C. Cole, R. Gorlick, E.A. Kolb, W. Zhang, R. Lock, H. Carol, M. Tajbakhsh, C.P. Reynolds, J.M. Maris, J. Courtright, S.T. Keir, H.S. Friedman, C. Stopford, J. Zeidner, J. Wu, T. Liu, C.A. Billups, J. Khan, S. Ansher, J. Zhang, and M.A. Smith The pediatric preclinical testing program: description of models and early testing results Pediatr. Blood Cancer 49 2007 928 940
25. H.J. Jones, D.I. Vernon, and S.B. Brown Photodynamic therapy effect of m-THPC (Foscan) in vivo: correlation with pharmacokinetics Brit. J. Cancer 89 2 2003 398 404
26. P. Cramers, M. Ruevekamp, H. Oppelaar, O. Dalesio, P. Baas, and F.A. Stewart Foscan uptake and tissue distribution in relation to photodynamic efficacy Brit. J. Cancer 88 2 2003 283 290
27. B.W. Pogue, J.A. O'Hara, E. Demidenko, C.M. Wilmot, I.A. Goodwin, B. Chen, H.M. Swartz, and T. Hasan Photodynamic therapy with verteporfin in the radiation-induced fibrosarcoma-1 tumor causes enhanced radiation sensitivity Cancer Res. 63 5 2003 1025 1033
28. O. Bourdon, I. Laville, D. Carrez, A. Croisy, P. Fedel, A. Kasselouri, P. Prognon, P. Legrand, and J. Blais Biodistribution of meta-tetra(hydroxyphenyl) chlorin incorporated into surface-modified nanocapsules in tumor-bearing mice Photoche. Photobiol. Sci. 1 9 2002 709 714
29. B.C. Wilson, and M.S. Patterson The physics biophysics and technology of photodynamic therapy Phys. Med. Biol. 53 9 2008 R61 109
30. T.M. Busch, E.P. Wileyto, M.J. Emanuele, F. Del Piero, L. Marconato, E. Glatstein, and C.J. Koch Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen Cancer Res. 62 24 2002 7273 7279
31. P. Heffeter, K. Bock, B. Atil, M.A. Reza Hoda, W. Korner, C. Bartel, U. Jungwirth, B.K. Keppler, M. Micksche, W. Berger, and G. Koellensperger Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339 J. Biol. Inorg. Chem. 15 5 2010 737 748
32. P.C. Bruijnincx, and P.J. Sadler New trends for metal complexes with anticancer activity Curr. Opin. Chem. Biol. 12 2 2008 197 206
33. T. Chen, Y. Liu, W.J. Zheng, J. Liu, and Y.S. Wong Ruthenium polypyridyl complexes that induce mitochondria-mediated apoptosis in cancer cells Inorg. Chem. 49 14 2010 6366 6368
34. M. Clarke Ruthenium metallopharmaceuticals Coord. Chem. Rev. 236 2003 209 233
35. M.J. Clarke, F. Zhu, and D.R. Frasca Non-platinum chemotherapeutic metallopharmaceuticals Chem. Rev. 99 9 1999 2511 2534
36. A.A. Rosenkranz, D.A. Jans, and A.S. Sobolev Targeted intracellular delivery of photosensitizers to enhance photodynamic efficiency Immunol. Cell Biol. 78 4 2000 452 464
37. H.J. Hopkinson, D.I. Vernon, and S.B. Brown Identification and partial characterization of an unusual distribution of the photosensitizer meta-tetrahydroxyphenyl chlorin (temoporfin) in human plasma Photochem. Photobiol. 69 4 1999 482 488
38. M. Sulyok, S. Hann, C. Hartinger, B. Keppler, G. Stingeder, and G. Koellensperger Two dimensional separation schemes for investigation of the interaction of an anticancer ruthenium(III) compound with plasma proteins J. Anal. Atom. Spectrom. 20 9 2005 856 863
39. N. Cetinbas, M.I. Webb, J.A. Dubland, and C.J. Walsby Serum-protein interactions with anticancer Ru(III) complexes KP1019 and KP418 characterized by EPR J. Biol. Inorg. Chem. 15 2 2010 131 145
40. B. Chen, T. Roskams, and P.A. de Witte Antivascular tumor eradication by hypericin-mediated photodynamic therapy Photochem. Photobiol. 76 5 2002 509 513
41. D.A. Bellnier, and T.J. Dougherty A preliminary pharmacokinetic study of intravenous Photofrin in patients J. Clin. Laser Med. Surg. 14 5 1996 311 314
42. S. Brown, D. Vernon, J. Holroyd, S. Marcus, R. Trust, W. Hawkins, A. Shah, and A. Tonelli P. Spinelli, M. Dal Fante, R. Marchesini, Pharmacokinetics of Photofrin in man 1992 Elsevier Science Amsterdam 475 479